Comparative Efficacy and Safety of Daily Versus Alternate-Day Dosing of Rosuvastatin in Diabetic Dyslipidemia: An Open-Label Clinical Trial
Cureus · 06.06.2025
DOI: 10.7759/cureus.85457 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cureus, erschienen am 06.06.2025. Verfasst von Nalini Kumari und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Apollo Institute of Medical Sciences and Research, Hyderabad, IND. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND: Cardiovascular disease (CVD) is a growing health concern among individuals with diabetes. Cardiovascular conditions tend to present earlier in Indian populations, and the prevalence of diabetes is increasing in the region. Type 2 diabetes (T2DM) is frequently linked to abnormal cholesterol (CH) levels, which can increase the risk of heart problems. Rosuvastatin is a medication often used to manage cholesterol and may offer dosing flexibility due to its long duration of action. AIMS AND OBJECTIVES: To compare the efficacy and safety of daily versus alternate-day dose of rosuvastatin in patients with T2DM. MATERIALS AND METHODS: The study was a single-center, prospective, open-label, parallel-group, randomized trial conducted over 12 weeks. The study enrolled 60 patients with diabetes-related dyslipidemia who were receiving care at a diabetic clinic within a tertiary care teaching center. Patients were randomized into two groups: group I received a daily dose and group II received an alternate-day dose of rosuvastatin. The primary endpoint was the percentage change in low-density lipoprotein cholesterol (LDL-C). Secondary endpoints included percentage changes in total cholesterol (TC), triglycerides (TGs), high-density lipoprotein cholesterol (HDL-C) levels, and adverse events over 12 weeks of treatment. Appropriate tests were applied, considering a significance level of p
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacology, Apollo Institute of Medical Sciences and Research, Hyderabad, IND.
- Department of Pharmacology, Government Medical College, Nagpur, IND.
- Department of Pharmacology, All India Institute of Medical Sciences, Nagpur, IND.
Zitieren
APA
Kumari, N., Shamkuwar, C. A., Motghare, V. M., & Dakhale, G. N. (2025). Comparative Efficacy and Safety of Daily Versus Alternate-Day Dosing of Rosuvastatin in Diabetic Dyslipidemia: An Open-Label Clinical Trial. Cureus. https://doi.org/10.7759/cureus.85457
Vancouver
Kumari N, Shamkuwar CA, Motghare VM, Dakhale GN. Comparative Efficacy and Safety of Daily Versus Alternate-Day Dosing of Rosuvastatin in Diabetic Dyslipidemia: An Open-Label Clinical Trial. Cureus. 2025. doi:10.7759/cureus.85457
BibTeX
@article{Kumari2025,
author = {Kumari, Nalini and Shamkuwar, Chetna A and Motghare, Vijay M and Dakhale, Ganesh N},
title = {Comparative Efficacy and Safety of Daily Versus Alternate-Day Dosing of Rosuvastatin in Diabetic Dyslipidemia: An Open-Label Clinical Trial},
journal = {Cureus},
year = {2025},
doi = {10.7759/cureus.85457}
}
EUVIMED